Device Trial Radar · NCT07203092
Effects of Transcranial Photobiomodulation in ADHD
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Sep 1, 2025
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Francisco Gonzalez-Lima, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 44 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.
Conditions
- Attention Deficit Hyperactivity Disorder
Interventions
Active transcranial photobiomodulationDevice
Active transcranial photobiomodulation to the forehead targeting prefrontal cortex involves administration of 1064-nm light delivered via laser with a 4 centimeter beam diameter and 250 mW/cm2 power density for 8 minutes per treatment.
Sham transcranial photobiomodulationDevice
Identical procedure as active group, but without 1064-nm light emitted by the device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Performance on the Continuous Performance TaskTime frame: 1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3).
- Prefrontal oxygenation (functional near-infrared spectroscopy)Time frame: 1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3).
- Scores on the Adult ADHD Self-Report Scale (ASRS) questionnaireTime frame: 1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3). 3. Follow-up: Four weeks later (Online).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas at Austin
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.